Cencora (COR) to Release Earnings on Wednesday

Cencora (NYSE:COR) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Cencora to post earnings of $4.07 per share and revenue of $75.41 billion for the quarter.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, analysts expect Cencora to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Cencora Price Performance

Cencora stock opened at $290.12 on Wednesday. Cencora has a 1 year low of $214.77 and a 1 year high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market cap of $56.26 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The firm has a 50-day moving average of $269.87 and a two-hundred day moving average of $250.27.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is currently 31.29%.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. This represents a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 50,223 shares of company stock worth $13,580,967. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on COR. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Morgan Stanley set a $288.00 target price on Cencora in a research report on Tuesday, April 15th. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Finally, UBS Group increased their target price on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $289.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.